+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Long-Acting Drug Delivery Technologies and Services Market Industry Trends and Global Forecasts to 2035, by Compatible Dosage Form, Principle, Strategy, Type of Molecule Delivered, Type of Material Used, and Key Geographical Regions

  • PDF Icon

    Report

  • 291 Pages
  • March 2025
  • Region: Global
  • Roots Analysis
  • ID: 5725728

The global long-acting drug delivery technologies and services market is estimated to grow from USD 1.06 billion in the current year to USD 4.62 billion by 2035, at a CAGR of 13.1% during the forecast period to 2035.

Long-Acting Drug Delivery Technologies and Services Market: Growth and Trends

Long-acting drug delivery systems are being widely adopted for sustained delivery of pharmaceutical drugs to treat a plethora of disease indications, including neurological diseases, infectious diseases, pulmonary diseases, ophthalmological diseases and opioid use disorders. These systems enable effective administration and improved efficacy of peptides, antibodies and vaccines. These novel delivery systems also enable the effective administration of macromolecules for a long-term effect, which are otherwise difficult to administer. Given the potential of long-acting drug delivery systems to improve patient compliance and adherence to medication, industry players have undertaken numerous initiatives to enable the clinical and commercial translation of long-acting drugs under development. This has led to the development of drugs that exhibit prolonged effects (for a few months or years). The application of long-acting therapeutics has the potential to benefit not only the patients but also the healthcare system. In particular, these formulations are beneficial to treat women living in low / middle income countries, as it will result in a substantial drop in the anticipated clinic visits and associated costs.

Furthermore, owing to the formulation and developmental challenges associated with complex dosage forms, the reliability of stakeholders having expertise in the long-acting drug delivery field has grown significantly. This will eventually aid drug developers to address bottlenecks stemming from conventional treatment options and improve the overall clinical outcome. Driven by the technological advancements in the field and rising demand for long-acting drugs, the long-acting drug delivery technologies and services market is anticipated to witness notable growth in the foreseen future.

Long-Acting Drug Delivery Technologies and Services Market: Key Insights

The report delves into the current state of the long-acting drug delivery technologies and services market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

  • At present, more than 100 long-acting drug delivery technologies are being offered by companies across the globe in order to develop long-acting drugs for a myriad of disease indications.

  • Nearly 90% of the technologies are based on manipulation of drug release profile; majority of these technologies can support the development of long-acting injectables with dosing intervals of at least a month.
  • In pursuit of gaining a competitive edge, industry stakeholders are actively innovating and developing novel long-acting drug delivery technologies that can be utilized across multiple therapeutic areas.
  • The current service providers landscape features the presence of over 40 companies, offering a wide range of development and manufacturing services for the long-acting delivery of drugs.
  • The market is fragmented, featuring the presence of both established players and small firms that have the expertise to develop / manufacture long-acting drugs / delivery systems for various dosage forms.
  • The growing interest in this domain is clearly evident from the rise in partnership activity; in fact, more than 60 collaborations related to long-acting drug delivery were inked in the last three years.
  • ~575 scientific articles published recently signify the focused efforts being led by researchers to identify and develop novel long-acting technologies and therapeutic interventions.
  • Over 1,200 patents related to long-acting drug delivery have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field.
  • 400+ grants have been awarded for the ongoing R&D efforts for long-acting drug delivery; University of North Carolina and John Hopkins University have emerged as the most popular recipient organizations.
  • The market opportunity associated with long-acting drug delivery technologies is anticipated to witness an annualized growth of nearly 13% over the next decade.

Long-Acting Drug Delivery Technologies and Services Market: Key Segments

Manipulation of Drug Release from Delivery Systems Occupy the Largest Share of the Long-Acting Drug Delivery Technologies and Services Market

Based on the principle, the market is segmented into manipulation of drug release from delivery systems and manipulation of in vivo clearance. At present, manipulation of drug release from delivery systems segment holds the maximum share of the long-acting drug delivery technologies and services market. This trend is unlikely to change in the near future.

Micro-Encapsulation is Likely to Dominate the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the strategy, the market is segmented into chemical modification, micro-encapsulation, long-acting hydrogels, long acting implants, long acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion. Currently, micro-encapsulation holds the maximum share of the long-acting drug delivery technologies and services market. This trend is unlikely to change in the near future. Further, the long-acting drug delivery technologies and services market for long-acting microneedles is likely to grow at a relatively higher CAGR.

Long Acting Injectables Occupy the Largest Share of the Long-Acting Drug Delivery Technologies and Services Market

Based on the compatible dosage form, the market is segmented into long acting injectables, long acting implantable, long-acting orals, long acting topicals / transdermals and other dosage forms. At present, long-acting injectables captures the highest share of the long-acting drug delivery technologies and services market. It is worth highlighting that long-acting drug delivery technologies and services market for implantable is likely to grow at relatively higher CAGR.

Small Molecules are the Fastest Growing Segment of the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the type of molecules delivered, the market is segmented into small molecules, biologics and other molecules. It is worth highlighting that, currently, small molecules hold a larger portion of the long-acting drug delivery technologies and services market. This trend is likely to remain the same in the coming decade.

Polymer based Materials are likely to Dominate the Long-Acting Drug Delivery Technologies and Services Market During the Forecast Period

Based on the type of material used, the market is segmented into polymer-based materials and non-polymer based materials. It is worth highlighting that majority of the current long-acting drug delivery technologies and services market is captured by the polymer-based materials.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Middle East and North Africa. The majority of the share is expected to be captured by players based in North America and Europe. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

The market sizing and opportunity analysis has been segmented across the following parameters:

Principle 

  • Manipulation of drug release from delivery systems
  • Manipulation of in vivo clearance 

Strategy 

  • Chemical Modification
  • Micro-encapsulation
  • Long-Acting Hydrogels
  • Long-Acting Implants
  • Long-Acting Microneedles
  • Multivesicular Liposomes
  • Nanocrystal Suspensions
  • Protein Fusion

Compatible Dosage Form

  • Long-Acting Injectables
  • Long-Acting Implantables
  • Long-Acting Oral,
  • Topical / Transdermal
  • Vaginal
  • Other Dosage Forms

Type of Molecule Delivered

  • Small Molecules
  • Biologics
  • Other Molecules

Type of Material Used 

  • Polymer based
  • Non-polymer based

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa

Key Players in the Long-Acting Drug Delivery Technologies and Services Market, Profiled in the Report Include:

  • Adare Pharma Solutions
  • AMW
  • Bostal Drug Delivery
  • Creative Biolabs
  • ForDoz Pharma
  • Innocore Pharmaceuticals
  • Integral BioSystems
  • LATITUDE Pharmaceuticals
  • Navin Saxena Research and Technology Centre (NSRT)
  • Samyang Biopharm

Long-Acting Drug Delivery Technologies and Services Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the long-acting drug delivery technologies and services market, focusing on key market segments, including principle, strategy, compatible dosage form, type of molecule delivered, type of material used and key geographical regions.
  • Market Landscape 1: A comprehensive evaluation of long-acting drug delivery technologies, considering various parameters, such as principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development, number of approved drugs and therapeutic area(s). Additionally, the chapter includes information on various technology developers, along with analysis based on multiple parameters, such as their year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).
  • Market Landscape 2: A comprehensive evaluation of contract service providers engaged in the long-acting drug delivery technologies and services market, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported.
  • Technology Competitiveness Analysis: A comprehensive competitive analysis of long-acting drugs delivery technologies, examining factors, such as developer power and technology strength.
  • Company Competitiveness Analysis: A comprehensive competitive analysis of long-acting drugs delivery service providers, examining factors, such as company strength and service strength.
  • Company Profiles: In-depth profiles of key industry players offering technologies and offering services in the field of long-acting drugs delivery, focusing on company overviews, technology portfolio, service portfolio, recent developments and an informed future outlook.
  • Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.
  • Publication Analysis: A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long acting drugs delivery, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).
  • Patent Analysis: Detailed analysis of various patents filed / granted related to long-acting drug delivery based on publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • Grant Analysis: A comprehensive evaluation of various grants that have been awarded to research institutes engaged in conducting research related to long-acting drug delivery, since 2018, based on various important parameters, such as year of grant award, amount awarded, support period, type of funding institute center, type of grant application, purpose of grant award, activity code, NIH spending category, study section involved, popular NIH departments (in terms of number of grants), type of recipient organization, prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants and amount awarded).

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks

4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported

6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis

12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

14. CONCLUSION15. INTERVIEW TRANSCRIPTS16. APPENDIX 1: TABULATED DATA17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Executive Summary: Technology Landscape
Figure 2.1 Executive Summary: Technology Landscape
Figure 2.2 Executive Summary: Service Providers Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Grant Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis (Technology)
Figure 2.8 Executive Summary: Market Forecast and Opportunity Analysis (Service)
Figure 3.1 Types of Long Acting Drug Delivery Systems
Figure 3.2 Principles and Strategies associated with Long Acting Drug Delivery
Figure 4.1 LADD Technologies: Distribution by Principle
Figure 4.2 LADD Technologies: Distribution by Strategy
Figure 4.3 LADD Technologies: Distribution by Type of Material Used
Figure 4.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Figure 4.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Figure 4.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Figure 4.7 LADD Technologies: Distribution by Highest Phase of Development
Figure 4.8 LADD Technologies: Distribution by Number of Approved Drugs
Figure 4.9 LADD Technologies: Distribution by Therapeutic Area(s)
Figure 4.10 LADD Technology Developers: Distribution by Year of Establishment
Figure 4.11 LADD Technology Developers: Distribution by Company Size
Figure 4.12 LADD Technology Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Technologies
Figure 5.1 LADD Contract Service Providers: Distribution by Year of Establishment
Figure 5.2 LADD Contract Service Providers: Distribution by Company Size
Figure 5.3 LADD Contract Service Providers: Distribution by Location of Headquarters
Figure 5.4 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 LADD Contract Service Providers: Distribution by Location of Facilities
Figure 5.6 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Figure 5.7 LADD Contract Service Providers: Distribution by Scale of Operation
Figure 5.8 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Figure 5.9 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Figure 5.10 LADD Contract Service Providers: Distribution by Service(s) Offered
Figure 5.11 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Figure 5.12 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Figure 5.13 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Figure 5.14 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Figure 6.1 Technology Competitiveness Analysis: LADD Technologies offered by Small Companies
Figure 6.2 Technology Competitiveness Analysis: LADD Technologies offered by Mid-sized Companies
Figure 6.3 Technology Competitiveness Analysis: LADD Technologies offered by Large Companies
Figure 6.4 Technology Competitiveness Analysis: LADD Technologies offered by Very Large Companies
Figure 7.1 Company Competitiveness Analysis: LADD Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: LADD Service Providers based in Europe
Figure 7.3 Company Competitiveness Analysis: LADD Service Providers based in Asia-Pacific
Figure 8.1 Adare Pharma Solutions: Service Portfolio
Figure 8.2 AMW: Service Portfolio
Figure 8.3 Bostal Drug Delivery: Service Portfolio
Figure 8.4 Creative Biolabs: Service Portfolio
Figure 8.5 ForDoz Pharma: Service Portfolio
Figure 8.6 InnoCore Pharmaceuticals: Service Portfolio
Figure 8.7 Integral BioSystems: Service Portfolio
Figure 8.8 LATITUDE Pharmaceuticals: Service Portfolio
Figure 8.9 Navin Saxena Research and Technology Centre (NSRT): Service Portfolio
Figure 8.10 Samyang Biopharm: Service Portfolio
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Regional Distribution
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.10 Partnerships and Collaborations: Local and International Deals
Figure 10.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Most Popular Journals: Distribution by Number of Publications
Figure 10.4 Most Popular Publishers: Distribution by Number of Publications
Figure 10.5 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.6 Most Popular Keywords: Distribution by Number of Publications
Figure 10.7 Key Funding Institutes: Distribution by Number of Publications
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Figure 11.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 11.4 Patent Analysis: Distribution by Geography
Figure 11.5 Patent Analysis: Distribution by CPC Symbols
Figure 11.6 Leading Industry Players: Distribution by Number of Patents
Figure 11.7 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 11.8 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 11.9 Patent Analysis: Distribution by Patent Age (2018-2022)
Figure 11.10 Patent Analysis: Patent Valuation
Figure 12.1 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Figure 12.2 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Figure 12.3 Grant Analysis: Distribution by Support Period
Figure 12.4 Grant Analysis: Distribution by Support Period and Funding Institute Center
Figure 12.5 Grant Analysis: Distribution by Type of Grant Application
Figure 12.6 Grant Analysis: Distribution by Purpose of Grant Award
Figure 12.7 Grant Analysis: Distribution by Activity Code
Figure 12.8 Word Cloud: NIH Spending Category
Figure 12.9 Grant Analysis: Distribution by Study Section Involved
Figure 12.10 Popular NIH Departments: Distribution by Number of Grants
Figure 12.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.12 Prominent Program Officers: Distribution by Number of Grants
Figure 12.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.14 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Figure 12.15 Grant Analysis: Distribution by Region of Recipient Organization
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global Long Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Figure 13.4 Long Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Figure 13.5 Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Figure 13.6 Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Figure 13.7 Long Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Figure 13.8 Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Figure 13.9 Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Figure 13.10 Long Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Figure 13.11 Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Figure 13.12 Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035 (USD Billion)
Figure 13.13 Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Figure 13.14 Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Figure 13.15 Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035 (USD Billion)
Figure 13.16 Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035 (USD Billion)
Figure 13.17 Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Figure 13.18 Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Figure 13.19 Long Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.20 Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Figure 13.21 Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Figure 13.22 Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.23 Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.24 Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Figure 13.25 Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Figure 13.26 Long Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Figure 13.27 Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Figure 13.28 Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Figure 13.29 Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Figure 13.30 Long Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Figure 13.31 Long Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Figure 13.32 Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Figure 13.33 Long Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.34 Long Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Figure 13.35 Long Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Figure 13.36 Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.37 Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Figure 13.38 Global Long Acting Drug Delivery Services Market, 2023-2035
Figure 13.39 Long Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.40 Long Acting Drug Delivery Services Market for Injectables, 2023-2035
Figure 13.41 Long Acting Drug Delivery Services Market for Implantables, 2023-2035
Figure 13.42 Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Figure 13.43 Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Figure 13.44 Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Figure 13.45 Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Figure 13.46 Long Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Figure 13.47 Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Figure 13.48 Long Acting Drug Delivery Services Market for Biologics, 2023-2035
Figure 13.49 Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Figure 13.50 Long Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.51 Long Acting Drug Delivery Services Market in North America, 2023-2035
Figure 13.52 Long Acting Drug Delivery Services Market in Europe, 2023-2035
Figure 13.53 Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
Figure 14.1 Concluding Remarks: Overall Technology Landscape
Figure 14.2 Concluding Remarks: Overall Service Providers Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Grant Analysis
Figure 14.7 Concluding Remarks: Market Forecast and Opportunity Analysis (Technology)
Figure 14.8 Concluding Remarks: Market Forecast and Opportunity Analysis (Service)

LIST OF TABLES
Table 4.1 LADD Technologies: Information on Principle
Table 4.2 LADD Technologies: Information on Strategy
Table 4.3 LADD Technologies: Information on Type of Material Used
Table 4.4 LADD Technologies: Information on Compatible Dosage Form(s)
Table 4.5 LADD Technologies: Information on Extended Dosing Interval(s)
Table 4.6 LADD Technologies: Information on Type of Molecule(s) Delivered
Table 4.7 LADD Technologies: Information on Highest Phase of Development
Table 4.8 LADD Technologies: Information on Approved Drugs
Table 4.9 LADD Technologies: Information on Therapeutic Area(s)
Table 4.10 LADD Technologies: List of Technology Developers
Table 5.1 LADD Contract Service Providers: List of Service Providers
Table 5.2 LADD Contract Service Providers: Information on Scale of Operation
Table 5.3 LADD Contract Service Providers: Information on Compatible Dosage Form(s)
Table 5.4 LADD Contract Service Providers: Information on Service(s) Offered
Table 5.5 LADD Contract Service Providers: Information on Type of Molecule(s) Supported
Table 8.1 List of Companies Profiled
Table 8.2 Adare Pharma Solutions: Company Overview
Table 8.3 Adare Pharma Solutions: Technology Portfolio
Table 8.4 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 8.5 AMW: Company Overview
Table 8.6 AMW: Technology Portfolio
Table 8.7 AMW: Recent Developments and Future Outlook
Table 8.8 Bostal Drug Delivery: Company Overview
Table 8.9 Bostal Drug Delivery: Technology Portfolio
Table 8.10 Creative Biolabs: Company Overview
Table 8.11 Creative Biolabs: Technology Portfolio
Table 8.12 Creative Biolabs: Recent Developments and Future Outlook
Table 8.13 ForDoz Pharma: Company Overview
Table 8.14 ForDoz Pharma: Technology Portfolio
Table 8.15 ForDoz Pharma: Recent Developments and Future Outlook
Table 8.16 InnoCore Pharmaceuticals: Company Overview
Table 8.17 InnoCore Pharmaceuticals: Technology Portfolio
Table 8.18 InnoCore Pharmaceuticals: Recent Developments and Future Outlook
Table 8.19 Integral BioSystems: Company Overview
Table 8.20 Integral BioSystems: Technology Portfolio
Table 8.21 Integral BioSystems: Recent Developments and Future Outlook
Table 8.22 LATITUDE Pharmaceuticals: Company Overview
Table 8.23 LATITUDE Pharmaceuticals: Technology Portfolio
Table 8.24 Navin Saxena Research and Technology Centre (NSRT): Company Overview
Table 8.25 Navin Saxena Research and Technology Centre (NSRT): Technology Portfolio
Table 8.26 Samyang Biopharm: Company Overview
Table 8.27 Samyang Biopharm: Technology Portfolio
Table 8.28 Samyang Biopharm: Recent Developments and Future Outlook
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Partner, 2018-2022
Table 9.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise), 2018-2022
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Codes
Table 11.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 11.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 13.1 Long Acting Drug Delivery Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2022 (USD Million)
Table 16.1 LADD Technologies: Distribution by Principle
Table 16.2 LADD Technologies: Distribution by Strategy
Table 16.3 LADD Technologies: Distribution by Type of Material Used
Table 16.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Table 16.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Table 16.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Table 16.7 LADD Technologies: Distribution by Highest Phase of Development
Table 16.8 LADD Technologies: Distribution by Number of Approved Drugs
Table 16.9 LADD Technologies: Distribution by Therapeutic Area(s)
Table 16.10 LADD Technology Developers: Distribution by Year of Establishment
Table 16.11 LADD Technology Developers: Distribution by Company Size
Table 16.12 LADD Technology Developers: Distribution by Location of Headquarters
Table 16.13 Most Active Players: Distribution by Number of Technologies
Table 16.14 LADD Contract Service Providers: Distribution by Year of Establishment
Table 16.15 LADD Contract Service Providers: Distribution by Company Size
Table 16.16 LADD Contract Service Providers: Distribution by Location of Headquarters
Table 16.17 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.18 LADD Contract Service Providers: Distribution by Location of Facilities
Table 16.19 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Table 16.20 LADD Contract Service Providers: Distribution by Scale of Operation
Table 16.21 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Table 16.22 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Table 16.23 LADD Contract Service Providers: Distribution by Service(s) Offered
Table 16.24 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Table 16.25 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Table 16.26 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Table 16.27 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Table 16.28 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.32 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 16.33 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 16.34 Most Active Players: Distribution by Number of Partnerships
Table 16.35 Partnerships and Collaborations: Regional Distribution
Table 16.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 16.37 Partnerships and Collaborations: Local and International Deals
Table 16.38 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 16.39 Publication Analysis: Distribution by Type of Publication
Table 16.40 Most Popular Journals: Distribution by Number of Publications
Table 16.41 Most Popular Publishers: Distribution by Number of Publications
Table 16.42 Most Popular Copyright Holders: Distribution by Number of Publications
Table 16.43 Key Funding Institutes: Distribution by Number of Publications
Table 16.44 Patent Analysis: Distribution by Type of Patent
Table 16.45 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Table 16.46 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.47 Patent Analysis: Distribution by Geography
Table 16.48 Patent Analysis: Distribution by CPC Symbols
Table 16.49 Leading Industry Players: Distribution by Number of Patents
Table 16.50 Patent Analysis: Cumulative Distribution by Type of Organization
Table 16.51 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 16.52 Patent Analysis: Distribution by Patent Age (2018-2022)
Table 16.53 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Table 16.54 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Table 16.55 Grant Analysis: Distribution by Support Period
Table 16.56 Grant Analysis: Distribution by Support Period and Funding Institute Center
Table 16.57 Grant Analysis: Distribution by Type of Grant Application
Table 16.58 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.59 Grant Analysis: Distribution by Activity Code
Table 16.60 Grant Analysis: Distribution by Study Section Involved
Table 16.61 Popular NIH Departments: Distribution by Number of Grants
Table 16.62 Grant Analysis: Distribution by Type of Recipient Organization
Table 16.63 Prominent Program Officers: Distribution by Number of Grants
Table 16.64 Popular Recipient Organizations: Distribution by Number of Grants
Table 16.65 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Table 16.66 Grant Analysis: Distribution by Region of Recipient Organization
Table 16.67 Global Long Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Table 16.68 Long Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Table 16.69 Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Table 16.70 Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Table 16.71 Long Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Table 16.72 Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Table 16.73 Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Table 16.74 Long Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Table 16.75 Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Table 16.76 Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035 (USD Billion)
Table 16.77 Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Table 16.78 Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Table 16.79 Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035 (USD Billion)
Table 16.80 Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035 (USD Billion)
Table 16.81 Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Table 16.82 Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Table 16.83 Long Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.84 Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Table 16.85 Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Table 16.86 Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Table 16.87 Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Table 16.88 Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Table 16.89 Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Table 16.90 Long Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Table 16.91 Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Table 16.92 Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Table 16.93 Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Table 16.94 Long Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Table 16.95 Long Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Table 16.96 Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Table 16.97 Long Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Table 16.98 Long Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Table 16.99 Long Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Table 16.100 Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 16.101 Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Table 16.102 Global Long Acting Drug Delivery Services Market, 2023-2035
Table 16.103 Long Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.104 Long Acting Drug Delivery Services Market for Injectables, 2023-2035
Table 16.105 Long Acting Drug Delivery Services Market for Implantables, 2023-2035
Table 16.106 Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Table 16.107 Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Table 16.108 Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Table 16.109 Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Table 16.110 Long Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Table 16.111 Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Table 16.112 Long Acting Drug Delivery Services Market for Biologics, 2023-2035
Table 16.113 Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Table 16.114 Long Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Table 16.115 Long Acting Drug Delivery Services Market in North America, 2023-2035
Table 16.116 Long Acting Drug Delivery Services Market in Europe, 2023-2035
Table 16.117 Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Adare Pharma Solutions
  • AMW
  • Bostal Drug Delivery
  • Creative Biolabs
  • ForDoz Pharma
  • Innocore Pharmaceuticals
  • Integral BioSystems
  • LATITUDE Pharmaceuticals
  • Navin Saxena Research and Technology Centre (NSRT)
  • Samyang Biopharm

Methodology

 

 

Loading
LOADING...